Search results for " liver disease"

showing 10 items of 559 documents

Detection of liver metastases in cancer patients with geographic fatty infiltration of the liver: the added value of contrast-enhanced sonography

2017

Purpose The aim of this study is to assess the role of contrast-enhanced ultrasonography (CEUS) in the detection of liver metastases in cancer patients with geographic liver fatty deposition on greyscale ultrasonography (US). Methods Thirty-seven consecutive cancer patients (24 women and 13 men; age, 33 to 80 years; mean, 58.1 years) with geographic liver fatty deposition, but without any detectable focal liver lesion on greyscale US, underwent sulphur hexafluoride-enhanced US. Two readers reported by consensus the presence, size, and location of any detected lesion. All patients underwent magnetic resonance imaging (MRI) as a confirmatory study. Sensitivity, specificity, positive and negat…

medicine.medical_specialtylcsh:Medical technologyNeoplasm metastasisContrast media; Fatty liver; Liver diseases; Liver neoplasms; Neoplasm metastasis; UltrasonographyLiver neoplasm030218 nuclear medicine & medical imagingLesionHemangioma03 medical and health sciences0302 clinical medicineText miningLiver neoplasmsPositive predicative valueFatty livermedicineRadiology Nuclear Medicine and imagingNeoplasm metastasiLiver diseasesUltrasonographymedicine.diagnostic_testbusiness.industryContrast mediaFatty liverCancerMagnetic resonance imagingmedicine.diseaseConfidence intervallcsh:R855-855.5030220 oncology & carcinogenesisOriginal ArticleRadiologymedicine.symptomSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessLiver diseaseUltrasonography
researchProduct

Rare <i>Atg7</i> Genetic Variants Predispose to Severe Fatty Liver Disease

2021

Background&Aims: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease and has a strong heritable component. The aim of this study was to identify new genes involved in NAFLD pathogenesis. Methods: We examined rare variants captured by whole-exome sequencing in individuals with severe fibrosis or hepatocellular carcinoma due to NAFLD (severe NAFLD, n=301) after variant prioritization.  We replicated the results in the UK Biobank and the Liver biopsy cohort (n=2268). Results: We observed an enrichment of the p.P426L variant (rs143545741 C>T; OR=7.2, 2.3-17.3; p C; MAF=0.060 vs. 0.035; OR=1.7, 1.2-2.5; p=0.003). In the UK Biobank cohort, the p.V471A variant wa…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryFatty livermedicine.diseaseChronic liver diseaseGastroenterologyPathogenesisLiver diseaseBallooning degenerationLiver biopsyInternal medicineHepatocellular carcinomamedicineSteatosisbusinessSSRN Electronic Journal
researchProduct

Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas

2006

Nonalcoholic fatty liver disease (NAFLD) is the most common cause for elevated liver enzymes in the developed nations. Beyond prevention programs which are of particular interest because of the increasing number of overweight children, treatment should be focussed on the most important risk factors, obesity and insulin resistance. As a consequence of elucidating the pathomechanisms of NAFLD, the number of potential therapeutic options increased. However, many studies investigating the therapeutic effect show shortcomings in at least one of the following points: lack of a serial liver biopsy, short term of treatment and limited number of included patients. The second generation insulin sensi…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryInsulinmedicine.medical_treatmentFatty liverGastroenterologyGeneral MedicineLiver transplantationmedicine.diseaseBioinformaticsEndocrinologyInsulin resistanceLiver biopsyInternal medicineNonalcoholic fatty liver diseasemedicineRosiglitazonebusinessPioglitazonemedicine.drugWorld Journal of Gastroenterology
researchProduct

Fat and liver transplantation: clinical implications

2018

Nonalcoholic steatohepatitis (NASH), with or without hepatocellular carcinoma, is a growing indication for liver transplantation (LT) worldwide, particularly in the Western world. Patients with NASH typically combine features of metabolic syndrome with cardiovascular comorbidities, which challenge pre-LT evaluation, surgical approaches, post-LT management, and outcomes. Post-LT survival in NASH patients is excellent, similar to that achieved with other indications, particularly in the absence of cardiovascular comorbidities. Although disease recurrence on the liver allograft is common, progression to advanced disease is uncommon, at least in the short term. Whether this holds true with long…

medicine.medical_specialtymedicine.medical_treatmentDisease030230 surgeryLiver transplantation03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRecurrenceNonalcoholic fatty liver diseasemedicineHumansIntensive care medicineTransplantationbusiness.industrymedicine.diseaseTissue DonorsLiver TransplantationNatural historysurgical procedures operativeHepatocellular carcinomaDonation030211 gastroenterology & hepatologySteatosisMetabolic syndromebusinessTransplant International
researchProduct

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

2020

Introduction We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). Methods ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. Results Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. Discussion Once AIH has been ruled out, the long-term outcomes and survival are un…

musculoskeletal diseasesMalemedicine.medical_specialtyAntibodies Antinuclear; Biopsy; England; Female; Humans; Italy; Longitudinal Studies; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prevalence; Prospective Studies; Survival AnalysisAnti-nuclear antibodyBiopsySettore MED/12 - GASTROENTEROLOGIAAntibodies Antinuclear Biopsy EnglandFemale Humans Italy Longitudinal Studies Male Middle Aged Non-alcoholic Fatty Liver Disease Prevalence Prospective StudiesSurvival AnalysisAutoimmune hepatitisMalignancyGastroenterologyAntibodies03 medical and health sciences0302 clinical medicineimmune system diseasesNon-alcoholic Fatty Liver DiseaseInternal medicineAntinuclearBiopsyNonalcoholic fatty liver diseasemedicineCarcinomaPrevalenceHumansLongitudinal StudiesProspective Studiesskin and connective tissue diseasesProspective cohort studySurvival analysisHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseases3. Good healthstomatognathic diseasesn/aEnglandItaly030220 oncology & carcinogenesisAntibodies Antinuclear030211 gastroenterology & hepatologyFemalebusiness
researchProduct

The impact of Nordic walking on bone properties in postmenopausal women with pre-diabetes and non-alcohol fatty liver disease

2021

This study investigated the impact of Nordic walking on bone properties in postmenopausal women with pre-diabetes and non-alcohol fatty liver disease (NAFLD). A total of 63 eligible women randomly participated in the Nordic walking training (AEx, n = 33), or maintained their daily lifestyle (Con, n = 30) during intervention. Bone mineral content (BMC) and density (BMD) of whole body (WB), total femur (TF), femoral neck (FN), and lumbar spine (L2-4) were assessed by dual-energy X-ray absorptiometry. Serum osteocalcin, pentosidine, receptor activator of nuclear factor kappa-B ligand (RANKL) levels were analyzed by ELISA assay. After an 8.6-month intervention, the AEx group maintained their BM…

naisetHealth Toxicology and MutagenesisEndocrinology Diabetes and Metabolismpostmenopausal womenbiomarkkeritAlcoholDiseases of the musculoskeletal systemWalkingDiseasesauvakävelychemistry.chemical_compound0302 clinical medicineAbsorptiometry PhotonBone DensityNon-alcoholic Fatty Liver DiseaseOrthopedics and Sports Medicine030212 general & internal medicineNordic walkingOsteoporosis PostmenopausalbiologykuntoliikuntaFemur Neckmusculoskeletal neural and ocular physiologyFatty liverRmusculoskeletal systemPostmenopausemedicine.anatomical_structureRANKLPre diabetesOsteocalcinMedicineFemaleikääntyneetmusculoskeletal diseasesmedicine.medical_specialtyluuntiheys030209 endocrinology & metabolismArticlePrediabetic State03 medical and health sciencesbone markersInternal medicinemedicineHumansFemurPentosidineFemoral neckPostmenopausal womenbusiness.industryPublic Health Environmental and Occupational Healthmedicine.diseaseEndocrinologyRC925-935chemistryei-alkoholiperäinen rasvamaksasairausbiology.proteinfatty liver diseasebone mineral densitybusinessaikuistyypin diabetesBone Reports
researchProduct

Betatrophin Levels Are Related to the Early Histological Findings in Nonalcoholic Fatty Liver Disease

2021

Betatrophin, a liver hormone, regulates glucose and lipid metabolism. We investigated the betatrophin levels in nonalcoholic fatty liver disease (NAFLD) and searched for any relationship with histological severity and metabolic parameters. Fifty males with NAFLD [Nonalcoholic Steatohepatitis (NASH) (n = 32)

nonalcoholic fatty liver disease0301 basic medicinemedicine.medical_specialtyBetatrophinEndocrinology Diabetes and Metabolismmedicine.medical_treatmentbetatrophin030209 endocrinology & metabolismMicrobiologydigestive systemBiochemistryArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceinsulin resistanceInternal medicineNonalcoholic fatty liver diseaseMedicineMolecular BiologyBetatrophin Glucose intolerance Insulin resistance Nonalcoholic fatty liver diseaseTriglyceridebusiness.industryInsulinnutritional and metabolic diseasesLipid metabolismmedicine.diseaseQR1-502digestive system diseases030104 developmental biologyEndocrinologyglucose intolerancechemistrySteatosisbusinessHormoneMetabolites
researchProduct

Etiological factors of chronic hepatitis in Italy: a 2014 national survey.

2017

Background The last Italian prevalence survey on chronic hepatitis (CH) conducted in 2001 showed that the hepatitis C virus (HCV) was the main agent associated with CH. Aim The aim of this study was to evaluate epidemiological changes in CH occurring after 13 years. Patients and methods Enrollment of 1392 CH consecutive patients referred to 16 Italian liver units in 2014 scattered all over the country (four in the North, four in the Center, four in the South, and four in the Islands) was performed. Results The mean age of the patients was 58.3 years, with a sex ratio (male/female) of 1.5. HCV infection (also with other etiologies) continues to be the most prevalent etiology (58.1%). However…

nonalcoholic fatty liver diseaseAdultMalemedicine.medical_specialtyPediatricsTime FactorsTime FactorAdolescentHepatitis C virusmedicine.disease_causemetabolic syndrome03 medical and health sciencesYoung Adult0302 clinical medicinechronic hepatitiRisk FactorsEpidemiologyNonalcoholic fatty liver diseasemedicinePrevalenceHumansAgedHepatitis ChronicHepatitisAged 80 and overHepatologybusiness.industryRisk FactorGastroenterologyEntecavirHepatitis CHealth SurveyHepatitis BHepatitis C ChronicMiddle Agedmedicine.diseaseHealth SurveysItaly030220 oncology & carcinogenesisEtiology030211 gastroenterology & hepatologyFemalehepatitis C virus infectionbusinessHumanmedicine.drugEuropean journal of gastroenterologyhepatology
researchProduct

MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver

2016

nonalcoholic fatty liver diseaseHepatologyHepatocellular carcinomabusiness.industrySettore MED/12 - GASTROENTEROLOGIAFatty liverGastroenterologyLocus (genetics)medicine.diseaseHepatocellular carcinoma; nonalcoholic fatty liver disease03 medical and health sciences0302 clinical medicineN/A030220 oncology & carcinogenesisHepatocellular carcinomaNonalcoholic fatty liver diseasemedicineCancer research030211 gastroenterology & hepatologybusinessDigestive and Liver Disease
researchProduct

Differences between current clinical guidelines for screening, diagnosis and management of non-alcoholic fatty liver disease and real-world practice:…

2021

International audience; INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease and is associated with obesity and metabolic comorbidities. Liver steatosis can progress to nonalcoholic steatohepatitis (NASH) exhibiting a relevant risk of fibrosis and ultimately liver failure. To date, no approved treatment for NASH to reduce its clinical and humanistic burden has been developed. AREAS COVERED: We undertook a literature review to identify English language, national and international clinical guidelines for NAFLD regarding diagnosis, assessment and management, and determined their points of agreement and difference. Additionally, we investigated published liter…

nonalcoholic fatty liver diseaseNonalcoholic steatohepatitismedicine.medical_specialtyliterature review[SDV]Life Sciences [q-bio]Liver fibrosisdigestive systemGastroenterologyDiagnosis DifferentialLiver diseasereal-world practiceLiver steatosisNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineHumansMass Screeningnonalcoholic steatohepatitisliver fibrosisHepatologybusiness.industryGastroenterologynutritional and metabolic diseasesfood and beveragesmedicine.diseaseObesitydigestive system diseases[SDV] Life Sciences [q-bio]clinical guidelinesPractice Guidelines as Topicbusiness
researchProduct